MacroGenics signs second major deal for DART technology, this one with Pfizer

Privately-held UA firm MacroGenics had another piece of good news this week, revealing that it has entered into a global research collaboration and license agreement with the world largest drugmaker, Pfizer (NYSE: PFE), to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.

Financial terms of the Pfizer deal were not disclosed, but earlier the same day MacroGenics reported a similar collaboration with Germany’s Boehringer Ingelheim, which provided the US firm with an upfront payment of $60 million and provision for $210 million for each program leading to successful DART products. This deal covers 10 multiple therapy area targets (The Pharma Letter October 27).

Under the terms of the Pfizer accord, MacroGenics will receive an upfront cash payment and research funding. In addition, it will be eligible to receive escalating preclinical, clinical, regulatory and commercial milestones as well as tiered royalties on sales of products resulting from the collaboration.